Drug Database
BE

bevacizumab (Abevmy / bevacizumab, Biocon / Krabeva)

✓ Approved

Mylan · VEGFA · Monoclonal Antibodies

What is bevacizumab?

bevacizumab is a monoclonal antibodies developed by Mylan. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesAbevmy, bevacizumab, Biocon, Krabeva
CompanyMylan
Drug ClassMonoclonal Antibodies, Antibody
Molecular TargetVEGFA
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Mylan

Mechanism of Action

Molecular Targets

bevacizumab acts on 1 molecular target:

VEGFAvascular endothelial growth factor A (VPF, MVCD1)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

bevacizumab is developed for 9 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer stage IV✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer metastatic✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Brain neoplasm malignant✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Fallopian tube cancer✓ Approved

+4 more indications available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedJournal of vitreoretinal diseases2026-09-19

Unilateral Fibrovascular Vitreoretinal Proliferation Associated With Retinal Astrocytic Hamartoma Revealing Tuberous Sclerosis Complex in Adulthood.

Özkan Efe Polat EP, Taş Aygar Gamze G, Çiçek Kaya Pınar P, Şekeryapan Gediz Berrak B

To report an unusual presentation of previously undiagnosed tuberous sclerosis complex manifesting as unilateral fibrovascular vitreoretinal proliferation associated with retinal astrocytic hamartoma complicated by vitreous hemorrhage (VH). A single case was reviewed. A 29-year-old woman presented with visual loss in the left eye and longstanding reduced vision since childhood. Examination revealed a retinal astrocytic hamartoma in the right eye and VH, fibrovascular vitreoretinal proliferation, retinal disorganization, and macular thickening in the left eye. Fluorescein angiography demonstrated telangiectatic vessels and late-phase leakage. The presence of accompanying cutaneous lesions prompted multidisciplinary evaluation, which revealed systemic tuberous sclerosis complex associated with a heterozygous TSC1 mutation. Following a single intravitreal injection of bevacizumab, regression of the VH and stabilization of the proliferative retinal findings were observed during 1 year of follow-up. Retinal astrocytic hamartomas associated with tuberous sclerosis complex are generally benign and asymptomatic; however, rare progressive forms may present with fibrovascular vitreoretinal proliferative complications. Ocular manifestations may play a critical role in diagnosing previously unrecognized tuberous sclerosis complex.

PMID 42761298
Read full article →
PubMedJournal of vascular and interventional radiology : JVIR2026-09-19

Interventional Radiology as the Most Utilized Treatment Specialty for Hepatocellular Carcinoma: A 25-Year Multidisciplinary Analysis at a High-Volume Academic Transplant Center.

Nadeem Arsalan A, Kulik Laura M LM, Kalyan Aparna A, Borja-Cacho Daniel D et al.

To characterize the longitudinal role of interventional radiology (IR) in multidisciplinary hepatocellular carcinoma (HCC) care over 25 years at a high-volume liver transplant center, and to evaluate changes in IR utilization and procedural composition following FDA approval of atezolizumab plus bevacizumab (Atezo/Bev) as first-line systemic therapy. This retrospective single-center cohort included patients 3,473 patients with HCC (ICD-9: 155.0; ICD-10: C22.0) treated between 2000 and 2025. The cohort was 71.7% male, with a median age of 64 years. Data were obtained from institutional procedure records and CPT codes. Outcomes included patients and procedures by specialty, IR procedural mix by era, treatment sequencing, and peri-transplant patterns. Analyses included descriptive statistics and chi-square tests. IR treated 2,520 (72.6%) and performed 4,313 procedures, including TARE (72.6%), TACE (18.7%), and ablation (7.9%). Surgery treated 1,350 (38.9%), medical oncology 746 (21.5%), and radiation oncology 96 (2.8%). Of 939 liver transplant patients, 510 (54.3%) received IR pre-transplant at a median of 201 days, primarily TARE (67.0%). After Atezo/Bev approval, IR patient proportion declined from 75.7% to 64.6% (p<0.001), while annual procedural volume remained stable (151 vs 192, p=0.366). TARE increased from 67.4% to 86.8% of procedures, while TACE decreased from 24.7% to 2.3%. Over 25 years, IR was the most utilized specialty in HCC care. TARE became the dominant locoregional and bridging therapy. After Atezo/Bev approval, IR utilization proportion declined, but procedural volume remained stable with a marked shift toward TARE and away from TACE.

PMID 42763097
Read full article →
PubMedMedicine2026-09-19

Nasal NUT carcinoma with repeated responses during multimodal treatment incorporating radiotherapy: A case report.

An Qi Q, Tao Yuxuan Y, Wang Peiguo P, Wang Zhongqiu Z

Nuclear protein in testis (NUT) carcinoma, formerly referred to as NUT midline carcinoma, is an exceptionally rare and aggressive malignancy. Evidence guiding radiotherapy-based management is limited, especially for nasal primary tumors with neuroaxis and systemic dissemination. A 40-year-old woman was referred after resection of a nasal cavity malignancy. During the subsequent course, she experienced orbital pain, headache, visual impairment, severe lumbar and radicular pain, bilateral lower-limb paralysis, urinary retention, malignant pleural effusion, and widespread metastatic disease. Pathologic consultation supported nasal NUT carcinoma, with positive NUT immunostaining and a Ki-67 index of approximately 70%. External molecular testing was reported to confirm a NUTM1 rearrangement, although the original report could not be obtained for review, and the assay platform and fusion partner could not be independently verified. After surgery, the patient received postoperative VMAT/IMRT to 70 Gy in 35 fractions with concurrent cisplatin. Following leptomeningeal, cauda equina, and extensive osseous dissemination, she received palliative helical IMRT/Tomotherapy craniospinal irradiation to 15 Gy in 10 fractions. A later VMAT plan delivered 30 Gy in 10 fractions to one lumbar and 2 hepatic targets. Pembrolizumab, bevacizumab, temozolomide, pleural drainage, and intrapleural therapy overlapped with different treatment phases. During the first course, headache severity decreased from 8/10 to 2.5/10 on a visual analog scale, and clinically recorded Snellen visual acuity improved from 20/200 to 20/50. Pain relief was documented after craniospinal irradiation and after the third treatment course. Serial imaging was contemporaneously interpreted as indicating interval reduction in selected lesions after radiation-containing multimodal treatment phases, although uniform retrospective remeasurement was not feasible. According to telephone follow-up with the patient's family, the patient died approximately 12 months after surgery. Repeated clinical and imaging responses were observed following multiple phases of multimodal treatment incorporating radiotherapy. Because systemic therapies were administered during overlapping periods, the independent contribution of radiotherapy could not be isolated. Radiotherapy may provide clinically meaningful local or palliative benefit as part of individualized multimodal treatment in selected patients.

PMID 42760727
Read full article →
PubMedCell biochemistry and biophysics2026-09-18

IER5L Facilitates the Progression of Hormone Receptor-Positive Breast Cancer by Inhibiting HSF1 Phosphorylation in Response to Bevacizumab.

Jia Wei W, Wang Haoqi H, Zhang Lina L, Yang Lixian L et al.

As the most frequently diagnosed cancer in women worldwide, breast cancer (BC) exhibits high heterogeneity, with hormone receptor-positive (HR+) tumors accounting for 60%-75% of all clinical BC cases. Despite extensive evaluation of bevacizumab (Bev) across BC subtypes, HR + BC remains a major clinical challenge. Given current therapeutic limitations, exploring Bev-related strategies offers promise for uncovering new vulnerabilities in HR + BC. In this study, treatment of the prototypical HR + BC cell line MCF-7 with Bev led to an enhanced invasive phenotype in these cells. Subsequent mRNA sequencing of MCF-7 cells revealed immediate early response 5-like (IER5L) as an upregulated gene in Bev-treated cells. Clinical analysis demonstrated that IER5L expression was significantly elevated in HR + BC tissue samples and that high IER5L levels were closely correlated with TNM stage. Functional characterization revealed that IER5L overexpression enhanced cell migration and invasion, concomitant with the induction of an epithelial-mesenchymal transition (EMT) phenotype. Furthermore, heat-shock factor 1 (HSF1), a known oncogenic driver, showed a positive correlation with IER5L in BC samples, and both proteins co-localized in the nuclear and cytoplasmic compartments. Mechanistically, IER5L suppressed phosphorylation of HSF1 at serine 307, and a phospho‑defective mutant (S307A) significantly enhanced the migratory and invasive phenotypes of BC cells. Collectively, these findings suggest that IER5L contributes to the malignant progression of HR + BC through modulation of HSF1 phosphorylation, thereby providing a promising therapeutic strategy for HR + BC.

PMID 42758435
Read full article →
PubMedFrontiers in oncology2026-09-18

Leptomeningeal metastasis from colon cancer: a case report and review of literature.

Wang Chao C, Wu Daixi D, Wang Aolin A, Zhang Xiaojia X et al.

Leptomeningeal metastasis from colorectal cancer (LM-CRC) is a rare condition characterized by poor outcomes and no established standard of care. We report a 60-year-old female patient who presented with constipation and abdominal pain. Eight months prior, she had been diagnosed with poorly differentiated adenocarcinoma of the sigmoid colon with focal signet-ring cell features, proficient mismatch repair, and a KRAS mutation. She had received treatment with FOLFOX/FOLFIRI ± bevacizumab. Five days before admission, she developed headache and vomiting. Contrast-enhanced brain MRI suggested leptomeningeal metastasis, which was confirmed by lumbar puncture cytology. Owing to progressive symptom deterioration, the patient did not receive any antitumor therapy timely and died two weeks after symptom onset. In this review, we summarize 29 cases of LM-CRC, aiming to characterize the pathology, symptoms, diagnosis, and survival data of LM-CRC in order to enhance clinicians' awareness of this rare disease. The incidence of LM-CRC is low and the prognosis is extremely poor; active anti-tumor therapy may prolong patient survival.

PMID 42755920
Read full article →
PubMedClinical case reports2026-09-18

Intracardiac Metastasis From a Testicular Yolk Sac Tumor With Brain and Pulmonary Involvement: A Multimodality Management Case Report.

Fazilat-Panah Danial D, Masudian Masume M, Heidarian Mina M

Cardiac metastasis from non-seminomatous germ cell tumors (NSGCTs) is exceedingly rare and represents an aggressive disease course. We report a 37-year-old man with a testicular yolk sac tumor who initially declined adjuvant therapy after orchiectomy. He later developed pulmonary metastases treated with BEP chemotherapy, followed by progressive disease with brain involvement requiring emergent decompressive craniectomy and whole-brain radiotherapy. Salvage TIP chemotherapy was administered. Persistent pulmonary disease led to thoracotomy, during which a discrete metastatic deposit in the right atrium was identified and surgically resected. Histopathology confirmed metastatic yolk sac tumor in all sites. The patient subsequently received maintenance therapy with oxaliplatin and bevacizumab. Follow-up has been based on clinical assessment and serial tumor marker monitoring, demonstrating ongoing biochemical and clinical stability for approximately 6 months following initiation of maintenance therapy, with the patient remaining on treatment at the time of this report. This case highlights the unpredictable metastatic behavior of NSGCTs and underscores the importance of multidisciplinary management in achieving disease control in rare and life-threatening metastatic presentations.

PMID 42756637
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about bevacizumab